George Institute for Global Health

New CEO for Merz Therapeutics: Stefan König

Retrieved on: 
Wednesday, March 1, 2023
Health, Neurology, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Liver, Multimedia, Growth, Therapy, Takeda Pharmaceutical Company, George Institute for Global Health, Merz, Pharmaceutical industry

As of immediately, Stefan König will be responsible for Merz Therapeutics GmbH as CEO and Managing Director.

Key Points: 
  • As of immediately, Stefan König will be responsible for Merz Therapeutics GmbH as CEO and Managing Director.
  • As one of the businesses of Merz Group, Merz Therapeutics provides medical solutions for the treatment of serious health conditions such as neurological health impairments or diseases of the liver.
  • Until recently, Stefan König held the position of President and CEO of George Medicines, a London-based company focusing on the development of pharmaceuticals in an advanced clinical phase.
  • The previous CEO and Managing Director of Merz Therapeutics, Stefan Brinkmann, is leaving Merz by best mutual agreement at the end of February after many years.

George Clinical to Accelerate International Growth Through Acquisition by Hillhouse

Retrieved on: 
Friday, December 9, 2022
Acquisition, BofA Securities, Clinical trial, Health, FIRB, Sale, Degenerative disease, Cancer, George Institute for Global Health, Eye, Pension, Hillhouse, Growth, Pharmaceutical industry, Fine chemical

Over the past several years, George Clinical has grown to be a leading APAC-born, global clinical research organization (CRO) providing clients access to the fastest growing clinical trial markets in the world.

Key Points: 
  • Over the past several years, George Clinical has grown to be a leading APAC-born, global clinical research organization (CRO) providing clients access to the fastest growing clinical trial markets in the world.
  • “Our acquisition by Hillhouse presents an immense opportunity for George Clinical to achieve even greater success in the next phase of our development.
  • Hillhouse expects to leverage its experience and relationships in the healthcare sector to augment George Clinical’s exposure to prospective high-quality biotech customers globally to drive increased clinical trial activity for George Clinical.
  • George Clinical is a leading global clinical research organization founded in Asia-Pacific driven by scientific expertise and operational excellence.

George Clinical Recruits More than 5,000 Patients in the Global Kidney Patient Trials Network

Retrieved on: 
Tuesday, October 25, 2022
George Institute for Global Health, AstraZeneca, Chronic kidney disease, Patient, Kidney, Research, Collection, Partnership, Goal, Kidney disease, Industry, Intention, GLOBE, Clinical trial, Global Health, CKD, CRO, Pharmaceutical industry

OVERLAND PARK, Ks., Oct. 25, 2022 (GLOBE NEWSWIRE) -- George Clinical, in close collaboration with The George Institute for Global Health, has recently announced the recruitment of more than 5,000 patients in its ground-breaking, first of its kind, Global Kidney Patient Trials Network (GKPTN) which will accelerate treatments for kidney disease.

Key Points: 
  • OVERLAND PARK, Ks., Oct. 25, 2022 (GLOBE NEWSWIRE) -- George Clinical, in close collaboration with The George Institute for Global Health, has recently announced the recruitment of more than 5,000 patients in its ground-breaking, first of its kind, Global Kidney Patient Trials Network (GKPTN) which will accelerate treatments for kidney disease.
  • In early 2020, the GKPTN enrolled its first patient with the purpose of developing a network of patients with chronic kidney disease (CKD) willing to participate in clinical research projects accessible through a single global chronic kidney disease platform.
  • The network establishes global infrastructure in a collaborative fashion to facilitate rapid and improved access to trials for patients with kidney disease.
  • George Clinical is a leading global clinical research organization founded in Asia-Pacific driven by scientific expertise and operational excellence.

George Medicines provides single-pill triple combination candidate for hypertension to VERONICA-Nigeria trial

Retrieved on: 
Wednesday, September 7, 2022
Mortality, Medical Research Council, University, COVID-19, Degenerative disease, National Health, Safety, Awareness, Associate, Death, George Institute for Global Health, Incidence, Systematic review, Kidney disease, Amlodipine, Hypertension, Prevalence, PLOS One, Blood pressure, Stroke, CMT, University of Cape Town, Drug development, Meta-analysis, Global Health, Indapamide, Pharmaceutical industry, Medical device, African, Patient

GMRx2 is George Medicines most advanced candidate in late-stage development.

Key Points: 
  • GMRx2 is George Medicines most advanced candidate in late-stage development.
  • A single-pill triple combination, it contains low doses of the commonly used hypertension medications telmisartan, amlodipine and indapamide.
  • The trial is funded through a programme grant from the National Health and Medical Research Council of Australia to The George Institute for Global Health.
  • J Hum Hypertens 2017; 31(8): 491-500
    Fixed Low-Dose Triple Combination Antihypertensive Medication vs Usual Care for Blood Pressure Control in Patients With Mild to Moderate Hypertension in Sri Lanka JAMA.

Clinical trial begins in the UK to investigate 3-in-1 high blood pressure pill

Retrieved on: 
Monday, January 17, 2022
Amlodipine, III, Indapamide, Patient, Research, Imperial College Healthcare NHS Trust, Academic clinical trial, George Institute for Global Health, Clinical trial, Pharmacology, International Society, Infarction, COVID-19, Guideline, Vascular dementia, Medical school, Safety, Death, Faculty, CEO, Stroke, World, School, NHS, Public health, Industry, Blood pressure, Imperial College Faculty of Medicine, Loma Linda University School of Public Health, Department of Nutrition, Cardiovascular disease, Type 2 diabetes, Heart, WHO, Medicine, Telmisartan, GP, International Society on Hypertension in Blacks, World Health Organization, Global Health, ICTU, Imperial College London, Hospital, Degenerative disease, Pharmaceutical industry, Hypertension

The phase III trial is the final stage of development, with results expected to support a regulatory filing for approval.

Key Points: 
  • The phase III trial is the final stage of development, with results expected to support a regulatory filing for approval.
  • Professor Ray leads a team of highly experienced operational staff to deliverexcellence in clinical trial management.
  • We are delighted to collaborate with Imperial Clinical Trials Unit to expand our research into the UK, where high blood pressure remains a significant silent killer and many patients are still uncontrolled.
  • A therapy that can more effectively control a patients blood pressure and reduce the significant pill burden that can lead patients to discontinue therapy could help transform how we treat high blood pressure.

Clinical trial begins in the UK to investigate 3-in-1 high blood pressure pill

Retrieved on: 
Monday, January 17, 2022
Amlodipine, III, Indapamide, Patient, Research, Imperial College Healthcare NHS Trust, Academic clinical trial, George Institute for Global Health, Clinical trial, Pharmacology, International Society, Infarction, COVID-19, Guideline, Vascular dementia, Medical school, Safety, Death, Faculty, CEO, Stroke, World, School, NHS, Public health, Industry, Blood pressure, Imperial College Faculty of Medicine, Loma Linda University School of Public Health, Department of Nutrition, Cardiovascular disease, Type 2 diabetes, Heart, WHO, Medicine, Telmisartan, GP, International Society on Hypertension in Blacks, World Health Organization, Global Health, ICTU, Imperial College London, Hospital, Degenerative disease, Pharmaceutical industry, Hypertension

The phase III trial is the final stage of development, with results expected to support a regulatory filing for approval.

Key Points: 
  • The phase III trial is the final stage of development, with results expected to support a regulatory filing for approval.
  • Professor Ray leads a team of highly experienced operational staff to deliverexcellence in clinical trial management.
  • We are delighted to collaborate with Imperial Clinical Trials Unit to expand our research into the UK, where high blood pressure remains a significant silent killer and many patients are still uncontrolled.
  • A therapy that can more effectively control a patients blood pressure and reduce the significant pill burden that can lead patients to discontinue therapy could help transform how we treat high blood pressure.